Novelos shutters executive office in reorganization; ApoCell sets up lab in Germany; InnoPharm nabs $20M loan;

@FierceBiotech: GeNO, uniQure look to leap through biotech IPO window in Q4 rush. More | Follow @FierceBiotech

@JohnCFierce: True, first wave of cancer vaccines has been a disappointment. Good reason for skepticism as well--but that's almost always the case. | Follow @JohnCFierce

@DamianFierce: Updated: Roche taps immatics in immunotherapy cancer R&D deal worth up to $1B. More | Follow @DamianFierce

@EmilyMFierce: Yale study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. News | Follow @EmilyMFierce

> Novelos Therapeutics is shuttering an executive office in Newton, MA, and putting its executive team in its existing facilities in Madison, WI. In a reorganization, the company, which ran into serious trouble back in 2010 following the failure of a lung cancer drug study, also named Simon Pedder as acting CEO and reduced the size of the board from 9 members to 5. Release

> Houston-based ApoCell, which has been working on tumor cell isolation tech, is setting up a lab in Leipzig, Germany, to collaborate more closely with the Fraunhofer Institute for Cell Therapy and Immunology. Story

> InnoPharm closed on a $20 million term loan facility provided by Athyrium Capital Management. Release

> San Diego-based Apricus Biosciences signed an exclusive license agreement with Laboratoires Majorelle to market Vitaros, its topical treatment for erectile dysfunction, in France, Monaco and certain African countries. Release

Medical Device News

@FierceMedDev: Syneron fattens revenue with slim-down, North American focus. More | Follow @FierceMedDev

@MarkHFierce: The latest weekly edition of FierceDiagnostics is ready for viewing. Check it out, and spread the word. Issue | Follow @MarkHFierce

@MichaelGFierce: Brain tumors succumb to drugs delivered via bone scaffold. News | Follow @MichaelGFierce

> Boston Scientific sets FDA date for closely watched Watchman. Article

> FDA slaps 'deadly' tag on Atossa's cancer Dx recall. Piece

> Syneron fattens revenue with slim-down, North American focus. More

> Myriad's melanoma Dx launch continues aggressive test rollout. Item

Pharma News

@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma

@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce

@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce

> 2013's story: Fewer drug approvals, better selling drugs. Article

> AstraZeneca wins, Merck and AbbVie lose with new statin-use guidelines. Story

> Is Endo on the verge of a Valeant-type acquisition binge? Article

> Sanofi tries label gambit to hold off Nasacort copies. More

Drug Delivery News

> MedImmune taps Unilife for wearable biologic injectable tech. Report

> DNA-delivering patch spurs bone growth. Story

> Study: Once-toxic peptide may deliver large molecules. Article

> Sustained-release glaucoma treatment nets $25M for Liquidia's Envisia. More

> Brain tumors succumb to drugs delivered via bone scaffold. Report

> Carbon nanotubes sneak drugs past gatekeeper proteins. Item

Diagnostics News

> Response Genetics sees disappointing Q3 as Dx revenue declines. Story

> VolitionRx, heartened by early data, shifts to multiple colorectal cancer Dx studies. Article

> Ex-Sequenom CEO seeks compensation in wake of scandal-related firing. More

> Oxford Immunotec's Dx milestones could supercharge IPO. Report

> Myriad gears up for melanoma test rollout. Story

> Myriad's signature BRCA test continues to generate lion's share of revenue. Item

Biomarkers News

> Study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. Story

> J&J, nonprofits fund new research into links between Down syndrome, Alzheimer's. More

> Protein in damaged tissue could be biomarker for muscular dystrophy. Article

> Biomarker could predict preeclampsia in pregnant women. Report

> U.K. crew eyes biomarker as flag for atrial fibrillation complications. Story

> Researchers flag protein biomarker for aggressive oral cancer. Item

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.